Minimal effects on immune parameters following chronic anti-TGF-beta monoclonal antibody administration to normal mice.
about
Synergistic enhancement of CD8+ T cell-mediated tumor vaccine efficacy by an anti-transforming growth factor-beta monoclonal antibody.Blockade of TGF-beta enhances tumor vaccine efficacy mediated by CD8(+) T cells.Blockade of transforming growth factor-beta1 accelerates lymphatic regeneration during wound repair.TGF-β-Neutralizing Antibody 1D11 Enhances Cytarabine-Induced Apoptosis in AML Cells in the Bone Marrow MicroenvironmentCharacterization of surgical models of postoperative tumor recurrence for preclinical adjuvant therapy assessmentRenoprotective effects of anti-TGF-β antibody and antihypertensive therapies in Dahl S ratsTransforming growth factor-beta1 suppresses airway hyperresponsiveness in allergic airway disease.Targeting transforming growth factor-beta signalingAn anti-transforming growth factor beta antibody suppresses metastasis via cooperative effects on multiple cell compartments.Homeostatic role of transforming growth factor-beta in the oral cavity and esophagus of mice and its expression by mast cells in these tissues.Transforming growth factor-beta signaling: emerging stem cell target in metastatic breast cancer?Antitransforming growth factor-beta therapy in fibrosis: recent progress and implications for systemic sclerosis.TGF-β receptor maintains CD4 T helper cell identity during chronic viral infectionsTransforming growth factor beta as a therapeutic target in systemic sclerosis.TGF-β in the Bone Microenvironment: Role in Breast Cancer Metastases.Transforming growth factor-β signaling in tumor initiation, progression and therapy in breast cancer: an update.The role of TGF-β in bone metastasis: novel therapeutic perspectives.Combined treatment with a transforming growth factor beta inhibitor (1D11) and bortezomib improves bone architecture in a mouse model of myeloma-induced bone disease.Novel therapeutic targets along the Th17 pathway.TGF-beta-neutralizing antibodies improve pulmonary alveologenesis and vasculogenesis in the injured newborn lung.Soluble betaglycan reduces renal damage progression in db/db mice.
P2860
Q33581597-110784FD-9EC0-4E8C-8AD0-300323692AEDQ33637647-97B90704-7773-4F64-B641-35F240E29ACDQ34358339-779A78DA-DA57-4C3C-9341-31A212E9CAD2Q34795604-85786348-E11F-478A-A159-1BDCD57C970FQ35964158-7E164495-9F5E-44BF-A62A-6AFAC92F9F8CQ36115290-406A111F-628C-4766-BBF3-34CBAC0D75EDQ36145788-E7789BF9-F973-44AC-A380-F2D933113F55Q36956092-96E24877-9128-4FEE-B3B5-687B1872B58AQ36983438-08846272-0837-4EF1-9FFF-454522687DB9Q37197348-B66DCED3-AF0D-4947-91F7-EDBF2A96CF63Q37219226-4225FCB2-1508-46EE-A1AD-99E4119BDEE8Q37306427-9D79E4DD-B78C-48C4-A111-4E9963423113Q37395668-2F43EA3B-0550-4F70-AAA4-CA09FFF4588EQ37428739-6CAD8B3D-A8EB-4A45-A5A5-A53961DC6130Q37900199-0C0F7F45-F748-4691-8F9F-2583ACFA34BFQ37918451-417E97A1-6EBA-4BCA-A30D-9C660BFF2843Q38129383-67DFC07D-D2C4-407B-9F2D-FFDB5D37EB81Q39595554-489E966B-04FF-40F2-BB73-4A052097D877Q46089932-E9C0DD07-8053-4018-B3B1-6505C82808A8Q48609503-8BF77089-1225-4D90-9158-B7DC269A2E7EQ50661031-CC899263-5494-44F1-A739-1D37C08FA6BA
P2860
Minimal effects on immune parameters following chronic anti-TGF-beta monoclonal antibody administration to normal mice.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh-hant
name
Minimal effects on immune para ...... administration to normal mice.
@en
Minimal effects on immune para ...... administration to normal mice.
@nl
type
label
Minimal effects on immune para ...... administration to normal mice.
@en
Minimal effects on immune para ...... administration to normal mice.
@nl
prefLabel
Minimal effects on immune para ...... administration to normal mice.
@en
Minimal effects on immune para ...... administration to normal mice.
@nl
P2093
P2860
P356
P1476
Minimal effects on immune para ...... administration to normal mice.
@en
P2093
Bruce Pratt
John McPherson
Melanie C Ruzek
Michael Hawes
Richard D Garman
Steve Ledbetter
Susan M Richards
P2860
P304
P356
10.1081/IPH-120020473
P577
2003-05-01T00:00:00Z